Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development.

Published on Dec 10, 2020in Cell38.637
· DOI :10.1016/J.CELL.2020.10.038
Katherine A. Donovan17
Estimated H-index: 17
(Harvard University),
Fleur M. Ferguson11
Estimated H-index: 11
(Harvard University)
+ 31 AuthorsEric S. Fischer29
Estimated H-index: 29
(Harvard University)
Summary Targeted protein degradation (TPD) refers to the use of small molecules to induce ubiquitin-dependent degradation of proteins. TPD is of interest in drug development, as it can address previously inaccessible targets. However, degrader discovery and optimization remains an inefficient process due to a lack of understanding of the relative importance of the key molecular events required to induce target degradation. Here, we use chemo-proteomics to annotate the degradable kinome. Our expansive dataset provides chemical leads for ∼200 kinases and demonstrates that the current practice of starting from the highest potency binder is an ineffective method for discovering active compounds. We develop multitargeted degraders to answer fundamental questions about the ubiquitin proteasome system, uncovering that kinase degradation is p97 dependent. This work will not only fuel kinase degrader discovery, but also provides a blueprint for evaluating targeted degradation across entire gene families to accelerate understanding of TPD beyond the kinome.
📖 Papers frequently viewed together
61 Citations
12.8k Citations
5 Citations
#1Jonathan W. Bushman (Harvard University)H-Index: 2
#2Katherine A. Donovan (Harvard University)H-Index: 17
Last. Eric S. Fischer (Harvard University)H-Index: 29
view all 8 authors...
Summary Deubiquitinating enzymes (DUBs) catalyze the removal of ubiquitin, thereby reversing the activity of E3 ubiquitin ligases and are central to the control of protein abundance and function. Despite the growing interest in DUBs as therapeutic targets, cellular functions for DUBs remain largely unknown and technical challenges often preclude the identification of DUB substrates in a comprehensive manner. Here, we demonstrate that treatment with potent DUB inhibitors coupled to mass spectrome...
8 CitationsSource
#1Peng Gao (WHU: Wuhan University)H-Index: 1
#2Ming-Ming Hu (WHU: Wuhan University)H-Index: 18
Last. Hong-Bing Shu (WHU: Wuhan University)H-Index: 70
view all 3 authors...
Abstract Upon detection of viral DNA, the cytoplasmic DNA sensor cyclic GMP-AMP (cGAMP) synthase (cGAS) utilizes GTP and ATP as substrates to synthesize the second messenger molecule 2′3′cyclic GMP-AMP (cGAMP), which binds to the ER-associated adaptor protein MITA/STING to signal innate antiviral response to DNA virus. How the cGAS-MITA pathways are post-translationally regulated is not fully understood. In this study, we identified the tyrosine kinase CSK as a positive regulator of cGAS-MITA me...
2 CitationsSource
#1Milka Kostic (Harvard University)H-Index: 4
#2Lyn H. Jones (Harvard University)H-Index: 33
Small molecules continue to dominate drug discovery because of their ease of use, lower cost of manufacturing, and access to intracellular targets. However, despite these advantages, small molecules are more likely to fail in clinical trials compared with biologicals and their development remains limited to a small subset of disease-relevant ‘druggable' targets. Targeted protein degradation has recently emerged as a novel pharmacological modality that promises to overcome small molecule limitati...
17 CitationsSource
#1Ivana Gasic (Harvard University)H-Index: 7
#2Brian J. Groendyke (Harvard University)H-Index: 3
Last. Timothy J. Mitchison (Harvard University)H-Index: 144
view all 8 authors...
Dysregulation of microtubules and tubulin homeostasis has been linked to developmental disorders, neurodegenerative diseases, and cancer. In general, both microtubule-stabilizing and destabilizing agents have been powerful tools for studies of microtubule cytoskeleton and as clinical agents in oncology. However, many cancers develop resistance to these agents, limiting their utility. We sought to address this by developing a different kind of agent: tubulin-targeted small molecule degraders. Deg...
8 CitationsSource
#2Nienke Moret (Harvard University)H-Index: 4
#3Changchang Liu (Harvard University)H-Index: 3
Last. Peter K. Sorger (Harvard University)H-Index: 101
view all 12 authors...
The functions of protein kinases have been heavily studied and inhibitors for many human kinases have been developed into FDA-approved therapeutics. A substantial fraction of the human kinome is nonetheless understudied. In this paper, members of the NIH Understudied Kinome Consortium mine public data on "dark" kinases to estimate the likelihood that they are functional. We start with a re-analysis of the human kinome and describe the criteria for creation of an inclusive set of 710 kinase domai...
4 CitationsSource
#1George M. Burslem (Yale University)H-Index: 15
#2Craig M. Crews (Yale University)H-Index: 86
New biological tools provide new techniques to probe fundamental biological processes. Here we describe the burgeoning field of proteolysis-targeting chimeras (PROTACs), which are capable of modulating protein concentrations at a post-translational level by co-opting the ubiquitin-proteasome system. We describe the PROTAC technology and its application to drug discovery and provide examples where PROTACs have enabled novel biological insights. Furthermore, we provide a workflow for PROTAC develo...
188 CitationsSource
ABSTRACT Because genetic alterations including mutations, overexpression, translocations, and dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this enzyme family is currently the subject of many drug discovery programs in the pharmaceutical industry. The US FDA approved four small molecule protein kinase antagonists in 2019; these include entrectinib, erdafitinib, pexidartinib, and fedratinib. Entrectinib binds to TRKA/B/C and ROS1 and is prescribed for the tr...
207 CitationsSource
#1Zhengnian Li (Harvard University)H-Index: 5
#2Benika J. Pinch (Harvard University)H-Index: 5
Last. Nathanael S. Gray (Harvard University)H-Index: 121
view all 13 authors...
Summary The G1/S cell cycle checkpoint is frequently dysregulated in cancer, leaving cancer cells reliant on a functional G2/M checkpoint to prevent excessive DNA damage. Wee1 regulates the G2/M checkpoint by phosphorylating CDK1 at Tyr15 to prevent mitotic entry. Previous drug development efforts targeting Wee1 resulted in the clinical-grade inhibitor, AZD1775. However, AZD1775 is burdened by dose-limiting adverse events, and has off-target PLK1 activity. In an attempt to overcome these limitat...
37 CitationsSource
#1Mei Zeng (Harvard University)H-Index: 6
#2Yuan Xiong (Harvard University)H-Index: 7
Last. Nathanael S. Gray (Harvard University)H-Index: 121
view all 19 authors...
Summary KRAS is the most frequently mutated oncogene found in pancreatic, colorectal, and lung cancers. Although it has been challenging to identify targeted therapies for cancers harboring KRAS mutations, KRASG12C can be targeted by small-molecule inhibitors that form covalent bonds with cysteine 12 (C12). Here, we designed a library of C12-directed covalent degrader molecules (PROTACs) and subjected them to a rigorous evaluation process to rapidly identify a lead compound. Our lead degrader su...
76 CitationsSource
Last. Daniel K. Nomura (University of California, Berkeley)H-Index: 59
view all 9 authors...
Targeted protein degradation (TPD) has emerged as a powerful tool in drug discovery for the perturbation of protein levels using heterobifunctional small molecules (i.e. PROTACs). E3 ligase recruiters remain central to this process yet relatively few have been identified relative to the >600 predicted human E3 ligases. While, initial recruiters have utilized non-covalent chemistry for protein binding, very recently covalent engagement to novel E3’s has proven fruitful in TPD application. Herein ...
2 CitationsSource
Cited By76
#1Maonan Wang (SEU: Southeast University)H-Index: 4
#2Jingzhou Zhao (SEU: Southeast University)
Last. Xuemei Wang (SEU: Southeast University)H-Index: 50
view all 6 authors...
Abstract null null Tumor-associated macrophages (TAM) are a large part of solid tumors and are an essential part of the tumor microenvironment, which can promote tumor growth, stimulate angiogenesis, and inhibit the immune response. The use of TAM as a therapeutic target to achieve the rational distribution of carriers in tumors and effectively inhibit tumors is the critical research direction of precise treatment pharmaceuticals. Therefore, it is imperative to realize the specific role of TAM i...
#1Michele Nardin (Institute of Science and Technology Austria)H-Index: 2
#2Jozsef Csicsvari (Institute of Science and Technology Austria)H-Index: 39
Last. Cristina Savin (NYU: New York University)H-Index: 9
view all 4 authors...
Although much is known about how single neurons in the hippocampus represent an animal9s position, how cell-cell interactions contribute to spatial coding remains poorly understood. Using a novel statistical estimator and theoretical modeling, both developed in the framework of maximum entropy models, we reveal highly structured cell-to-cell interactions whose statistics depend on familiar vs.\ novel environment. In both conditions the circuit interactions optimize the encoding of spatial inform...
1 CitationsSource
#1Wen Zhang (Harvard University)H-Index: 45
#2S. S. Roy Burman (Harvard University)
Last. Eric S. Fischer (Harvard University)H-Index: 29
view all 12 authors...
Targeted protein degradation (TPD) has rapidly emerged as a therapeutic modality to eliminate previously undruggable proteins by repurposing the cell9s endogenous protein degradation machinery. However, the susceptibility of proteins for targeting by TPD approaches, termed "degradability", is largely unknown. Recent systematic studies to map the degradable kinome have shown differences in degradation between kinases with similar drug-target engagement, suggesting yet unknown factors influencing ...
#1Pablo Oteiza (MPG: Max Planck Society)H-Index: 2
#2Maude W. Baldwin (MPG: Max Planck Society)H-Index: 8
Sensory systems evolve and enable organisms to perceive their sensory Umwelt, the unique set of cues relevant for their survival. The multiple components that comprise sensory systems - the receptors, cells, organs, and dedicated high-order circuits - can vary greatly across species. Sensory receptor gene families can expand and contract across lineages, resulting in enormous sensory diversity. Comparative studies of sensory receptor function have uncovered the molecular basis of receptor proper...
#1Nadine Russ (SGC: Structural Genomics Consortium)
#2Martin Schröder (SGC: Structural Genomics Consortium)H-Index: 7
Last. Susanne Müller (SGC: Structural Genomics Consortium)H-Index: 54
view all 11 authors...
CASK (Ca2+/calmodulin-dependent Ser/Thr kinase) is a member of the MAGUK (membrane-associated guanylate kinase) family that functions as neurexin kinases with roles implicated in neuronal synapses and trafficking. The lack of a canonical DFG motif, which is altered to GFG in CASK, led to the classification as a pseudokinase. However, functional studies revealed that CASK can still phosphorylate substrates in the absence of divalent metals. CASK dysfunction has been linked to many diseases, inclu...
#1Yingwen Chen (Ha Tai: Xiamen University)
#2Weizhou Qian (Ha Tai: Xiamen University)
Last. Chaoyong Yang (SJTU: Shanghai Jiao Tong University)H-Index: 23
view all 9 authors...
#1Imlirenla Pongener (Keele University)
#2Conor O'Shea (Keele University)
Last. Gavin J. Miller (Keele University)H-Index: 14
view all 5 authors...
Heparin and heparan sulfate represent key members of the glycosaminoglycan family of carbohydrates and underpin considerable repertoires of biological importance. As such, their efficiency of synthesis represents a key requirement, to further understand and exploit the H/HS structure-to-biological function axis. In this review we focus on chemical approaches to and methodology improvements for the synthesis of these essential sugars (from 2015 onwards). We first consider advances in accessing th...
#1Ricardo Augusto Massarico Serafim (University of Tübingen)
#2Jonathan M. Elkins (University of Oxford)H-Index: 29
Last. Matthias Gehringer (University of Tübingen)H-Index: 12
view all 5 authors...
Over 20 years after the approval of the first-in-class protein kinase inhibitor imatinib, the biological function of a significant fraction of the human kinome remains poorly understood while most research continues to be focused on few well-validated targets. Given the strong genetic evidence for involvement of many kinases in health and disease, the understudied fraction of the kinome holds a large and unexplored potential for future therapies. Specific chemical probes are indispensable tools ...
1 CitationsSource
#1Zhesheng He (CAS: Chinese Academy of Sciences)H-Index: 4
#2Fei Ye (National Health and Family Planning Commission)H-Index: 2
Last. Bo He (ShanghaiTech University)
view all 22 authors...
Abstract null We firstly disclose single compound yields better therapeutic outcome than Remdesivir in COVID-19 hamster treatments as it is armed with direct inhibition viral replication and intrinsic suppression inflammatory cytokines expression. Crystal data reveals that Au (I), released from Au22Glutathione18 (GA), covalently binds thiolate of Cys145 of SARS-CoV-2 Mpro. GA directly decreases SARS-CoV-2 viral replication (EC50: ~0.24 μM) and intrinsically down-regulates NFκB pathway therefore ...
#1Bridget P Belcher (Novartis)
#2Carl C. WardH-Index: 7
Last. Daniel K. NomuraH-Index: 59
view all 3 authors...
Targeted protein degradation (TPD) using proteolysis targeting chimeras (PROTACs) and molecular glue degraders has arisen as a powerful therapeutic modality for eliminating disease-causing proteins from cells. PROTACs and molecular glue degraders employ heterobifunctional or monovalent small molecules, respectively, to chemically induce the proximity of target proteins with E3 ubiquitin ligases to ubiquitinate and degrade specific proteins via the proteasome. Whereas TPD is an attractive therape...